

PharmaCielo to Hold Conference Call to Review Second Quarter 2020 Financial Results

TORONTO and RIONEGRO, Colombia, Aug. 18, 2020 /CNW/ - **PharmaCielo Ltd.** ("**PharmaCielo**" or the "**Company**") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it will host a conference call on Monday, August 31st, 2020, at 8:30 a.m. ET to discuss its second quarter financial results and provide investors with key business highlights. The call will be chaired by David Attard, CEO, Henning Von Koss, President, David Gordon, CCO and Scott Laitinen, CFO.

CONFERENCE CALL DETAILS

Date: August 31st, 2020 | Time: 8:30am ET

Participant Dial-in: 416-764-8650 or 1-888-664-6383

Replay Dial-in: 416-764-8677 or 1-888-390-0541

Conference ID: 11880297

Playback #: 880297 (Expires September 14th, 2020)

Listen to webcast: event.on24.com

About PharmaCielo

PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing centre located in Rionegro, Colombia.

The board of directors and executive team of PharmaCielo are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location plays in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PharmaCielo Ltd.

View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/August2020/18/c0206.html>

%SEDAR: 00038848E

For further information: David Gordon, Chief Corporate Officer, +1 416-864-6116,

www.PharmaCielo.com; Media Relations: International: Gal Wilder, Cohn & Wolfe, +1 647-259-3261, gal.wilder@cohnwolfe.ca; Colombia: Giselle Díaz Bermúdez, SPR Group, + 57 310 859 5468, Giselle.diaz@sprgroup.biz; Investor Inquiries: investors@pharmacielo.com

CO: PharmaCielo Ltd.

CNW 07:30e 18-AUG-20